Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$2.14 +6.5%	$1.93	$1.55 ▼ $5.41	$9.39M	0.94	171,608 shs	25,391 shs
LFLY Leafly	$2.22 +6.7%	$2.96	$1.96 ▼ $16.00	$4.79M	1.06	105,279 shs	46,129 shs
MTBC CareCloud		$3.10	$2.50 ▼ $6.75	$47.64M	0.85	63,000 shs	66,900 shs
ONPH Oncology Pharma	$0.00	$0.00	$0.00 ▼ $1.05	$20K	-0.91	3,907 shs	540 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+3.38%	-18.63%	+28.14%	+15.05%	-26.46%
LFLY Leafly	+6.73%	-19.57%	-11.55%	-51.84%	-68.26%
MTBC CareCloud	0.00%	0.00%	0.00%	0.00%	0.00%
ONPH Oncology Pharma	0.00%	-50.00%	+150.00%	+400.00%	-99.72%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	3.6372 of 5 stars	3.5	5.0	0.0	0.0	4.2	1.7	1.3
LFLY Leafly	2.1444 of 5 stars	3.3	5.0	0.0	0.0	2.9	0.8	0.0
MTBC CareCloud	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONPH Oncology Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	3.00	Buy	$7.00	227.10% Upside
LFLY Leafly	2.50	Moderate Buy	$6.00	170.27% Upside
MTBC CareCloud	N/A	N/A	N/A	N/A
ONPH Oncology Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ONPH, LFLY, MTBC, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/1/2024	LFLY Leafly	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $6.00
3/7/2024	ATHE Alterity Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$4.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	$3.37M	2.97	N/A	N/A	$3.78 per share	0.57
LFLY Leafly	$42.25M	0.12	N/A	N/A	($5.72) per share	-0.39
MTBC CareCloud	$139.60M	0.00	N/A	2.43	$6.58 per share	0.00
ONPH Oncology Pharma	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$9.30M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
LFLY Leafly	-$9.50M	-$4.92	N/A	∞	N/A	-22.48%	N/A	-39.85%	5/9/2024 (Estimated)
MTBC CareCloud	$2.84M	-$0.45	N/A	N/A	N/A	3.20%	4.54%	3.33%	N/A
ONPH Oncology Pharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
LFLY Leafly	N/A	N/A	N/A	N/A	N/A
MTBC CareCloud	N/A	N/A	N/A	N/A	N/A
ONPH Oncology Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	4.89	N/A
LFLY Leafly	N/A	3.74	3.74
MTBC CareCloud	N/A	1.21	1.19
ONPH Oncology Pharma	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
LFLY Leafly	15.55%
MTBC CareCloud	19.68%
ONPH Oncology Pharma	N/A

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
LFLY Leafly	11.30%
MTBC CareCloud	34.90%
ONPH Oncology Pharma	18.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	11	4.67 million	2.86 million	Not Optionable
LFLY Leafly	130	2.30 million	2.04 million	Optionable
MTBC CareCloud	4,100	15.22 million	9.91 million	Not Optionable
ONPH Oncology Pharma	1	38.66 million	31.70 million	Not Optionable

ONPH, LFLY, MTBC, and ATHE Headlines

Source	Headline
	2 business moves pulling physicians from care, per 1 oncology leader beckershospitalreview.com - April 18 at 12:24 PM
	Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement markets.businessinsider.com - April 17 at 8:53 PM
	How immuno-oncology is changing cancer care by harnessing the power of patients’ natural defenses dispatch.com - April 15 at 6:28 AM
	Nuclear Medicine Is Big Pharma’s New Target in Cancer Race bloomberg.com - April 12 at 7:30 AM
	Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment businesswire.com - April 10 at 10:31 AM
	Boehringer Ingelheim Upbeat On China, Forms Cancer Drug Partnership msn.com - April 9 at 9:39 PM
	Most Cancer Drugs Granted Accelerated Approval Don’t Confer a Clinical Benefit cancertherapyadvisor.com - April 9 at 1:42 PM
	AACR News: Pancreatic Cancer Outcomes May Improve with Presurgical Nivolumab/Chemo Combo genengnews.com - April 8 at 8:26 AM
	5 Successful Phase III Oncology Trials in Q1 biospace.com - April 8 at 1:56 AM
	Oncology Practice and Lab to Pay $4 Million in Kickback Case medscape.com - April 5 at 6:46 AM
	Kintara and TuHURA enter merger deal to advance oncology pipeline msn.com - April 4 at 9:00 PM
	Cancer biotech firm Alterome Therapeutics raises $132 mln in Goldman Sachs-led round msn.com - April 4 at 9:15 AM
	A new hope in immunotherapy against cancer msn.com - April 4 at 9:15 AM
	Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020 thelancet.com - April 1 at 2:57 PM
	FDA Makes Strides in Oncology: New Approvals and Promising Developments in March 2024 targetedonc.com - April 1 at 10:35 AM
	Regulatory tracker: AZ, Sanofi's Beyfortus cleared to protect babies from RSV in Japan fiercepharma.com - March 29 at 12:33 AM
	Regeneron's blood cancer therapy faces setback as FDA raises trial concerns msn.com - March 26 at 1:10 AM
	FDA declines to approve blood cancer drug over trial concerns beckershospitalreview.com - March 25 at 8:09 PM
	US FDA declines to approve Regeneron's blood cancer therapy msn.com - March 25 at 7:42 AM
	Structures of new cancer drug candidates revealed cen.acs.org - March 23 at 10:03 AM
	Oncology Pharma stock-selling scheme ends in consent agreement bioworld.com - March 22 at 9:01 AM
	Clinical trial results show new Penn technology could be the key to fighting brain cancer bizjournals.com - March 21 at 4:00 AM
	Thyme Care unveils oncology practice partner network to scale value-based care fiercehealthcare.com - March 15 at 5:09 PM
	AbilityPharma receives funds to advance pancreatic cancer trial msn.com - March 12 at 5:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alterity Therapeutics

NASDAQ:ATHE

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Leafly

NASDAQ:LFLY

Leafly Holdings, Inc. owns and operates a platform to provide consumers with cannabis information and connects consumers to cannabis brands and licensed retailers. The company offers subscription-based marketplace listings, digital advertising solutions, and software as a service-based tools to cannabis retailers; and information, reviews, menus, and ordering and delivery options to its audience through its website and mobile applications. Leafly Holdings, Inc. was founded in 2010 and is headquartered in Seattle, Washington.

CareCloud

NASDAQ:MTBC

CareCloud, Inc. brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows, and make better business and care decisions. More than 40,000 providers across the United States count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Services and solutions include revenue cycle management (RCM), practice management (PM), electronic health record (EHR), business intelligence, telehealth, and patient experience management (PXM). CareCloud is headquartered in Somerset, NJ.

Oncology Pharma

OTCMKTS:ONPH

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial